Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density Nasdaq:ATOS

KeepHealthCare.ORG – Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density Nasdaq:ATOS SEATTLE, June 26, 2018 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (ATOS) (“Atossa” Continue reading

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting

KeepHealthCare.ORG – Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Continue reading

SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients

KeepHealthCare.ORG – SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients Phase 2b trial met key clinical Continue reading

Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer

KeepHealthCare.ORG – Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer CALGARY, Alberta and SAN DIEGO, May 10, 2018 Continue reading

Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study Nasdaq:ATOS

KeepHealthCare.ORG – Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study Nasdaq:ATOS SEATTLE, April 30, 2018 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (Nasdaq:ATOS) Continue reading